Walter Masson, Leandro Barbagelata, Augusto Lavalle-Cobo, Pablo Corral, Juan P Nogueira
The role of lipoprotein(a) [Lp(a)] as a possible causal risk factor for atherosclerotic artery disease and aortic valve stenosis has been well established. However, the information on the association between Lp(a) levels and heart failure (HF) is limited and controversial. The main objective of the present study was to assess the association between Lp(a) levels and HF. This systematic review was performed according to PRISMA guidelines. A literature search was performed to detect studies that evaluated the association between Lp(a) levels and HF...
July 19, 2023: Heart Failure Reviews
Wahab J Khan, Jose Arriola-Montenegro, Melinda S Mutschler, Daniel Bensimhon, Robert Halmosi, Kalman Toth, Tamas Alexy
The prevalence of heart failure (HF) continues to rise in developed nations. Symptomatic congestion is the most common reason for patients to seek medical attention, and management often requires intravenous (IV) diuretic administration in the hospital setting. Typically, the number of admissions increases as the disease progresses, not only impacting patient survival and quality of life but also driving up healthcare expenditures. pH-neutral furosemide delivered subcutaneously using a proprietary, single-use infusor system (Furoscix) has a tremendous potential to transition in-hospital decongestive therapy to the outpatient setting or to the patient's home...
July 13, 2023: Heart Failure Reviews
Yu Gao, Ruiting Wang, Jinchi Jiang, Yueyao Hu, Haijing Li, Yong Wang
Anthracyclines and trastuzumab are widely used to treat breast cancer but increase the risk of cardiomyopathy and heart failure. With the use of trastuzumab and anthracycline-containing medications, this study intends to evaluate the effectiveness and security of current treatments against cardiotoxicity. We conducted a systematic review of randomized controlled trials (RCTs), which used at least one angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or beta-blocker (BB) to prevent cardiotoxicity of antineoplastic agents for breast cancer, in 4 databases (PubMed, Cochrane Library, EMBASE, Web of Science) from inception to 11 May 2022, without language restrictions...
July 7, 2023: Heart Failure Reviews
Konstantinos Dean Boudoulas, Filippos Triposkiadis, Sara Koenig, Konstantinos Marmagkiolis, Cezar Iliescu, Antonios Pitsis, Harisios Boudoulas
Acute severe mitral regurgitation (MR) is rare, but often leads to cardiogenic shock, pulmonary edema, or both. Most common causes of acute severe MR are chordae tendineae (CT) rupture, papillary muscle (PM) rupture, and infective endocarditis (IE). Mild to moderate MR is often seen in patients with acute myocardial infarction (AMI). CT rupture in patients with floppy mitral valve/mitral valve prolapse is the most common etiology of acute severe MR today. In IE, native or prosthetic valve damage can occur (leaflet perforation, ring detachment, other), as well as CT or PM rupture...
July 6, 2023: Heart Failure Reviews
Masatsugu Okamura, Masashi Shimizu, Shuhei Yamamoto, Kenichi Nishie, Masaaki Konishi
The effects of high-intensity interval training (HIIT) in patients with heart failure (HF) remain controversial. This systematic review and meta-analysis aimed to examine the efficacy of HIIT versus moderate-intensity continuous aerobic training (MCT) on exercise tolerance in patients with HF. We searched for studies published up to 4 March 2022 in Embase, MEDLINE, PubMed, and the Cochrane Library with no limitations on data, language, or publication status. We included randomized controlled trials comparing the efficacy of HIIT and MCT on peak oxygen uptake (VO2 ), as a measure of exercise tolerance...
September 2023: Heart Failure Reviews
Khalifah A Aldawsari, Abdullah N Alhuzaimi, Mohammad T Alotaibi, Dimpna C Albert-Brotons
Endocardial fibroelastosis (EFE) is a rare cardiac condition characterized by excessive endocardial thickening secondary to fibroelastic tissues that commonly present in infants and young children. Most of endocardial fibroelastosis cases are secondary forms, which occur in conjunction with other cardiac diseases. Endocardial fibroelastosis has been associated with poor prognosis and outcomes. In light of recent advancements in understanding pathophysiology, several new data have revealed compelling evidence that abnormal endothelial-to-mesenchymal transition is the root cause of endocardial fibroelastosis...
September 2023: Heart Failure Reviews
Hiroaki Hiraiwa, Daisuke Kasugai, Takahiro Okumura, Toyoaki Murohara
Studies over recent years have redeveloped our understanding of uremic cardiomyopathy, defined as left ventricular hypertrophy, congestive heart failure, and associated cardiac hypertrophy plus other abnormalities that result from chronic kidney disease and are often the cause of death in affected patients. Definitions of uremic cardiomyopathy have conflicted and overlapped over the decades, complicating the body of published evidence, and making comparison difficult. New and continuing research into potential risk factors, including uremic toxins, anemia, hypervolemia, oxidative stress, inflammation, and insulin resistance, indicates the increasing interest in illuminating the pathways that lead to UC and thereby identifying potential targets for intervention...
September 2023: Heart Failure Reviews
Christian Basile, Stefania Paolillo, Paola Gargiulo, Federica Marzano, Santo Dellegrottaglie, Vincenza Abbate, Antonio Ambrosio, Francesca Carbone, Simona Dell'Aversana, Immacolata Esposito, Maria Francesca Fierro, Pasquale Perrone-Filardi
BACKGROUND: In patients affected by heart failure (HF) with reduced ejection fraction (HFrEF), pharmacological treatments have been proven to alleviate symptoms and improve prognosis, while no treatment other than sodium-glucose co-transporter-2 inhibitors have demonstrated significant effects in HF with preserved ejection fraction (HFpEF). Left atrium decompression devices (LADd) have been recently investigated as a new interventional approach in patients with HFpEF. OBJECTIVES: To assess the efficacy of LADd on soft endpoints in HF patients across the spectrum of ejection fraction...
September 2023: Heart Failure Reviews
Rosa Lillo, Francesca Graziani, Francesco Franceschi, Giulia Iannaccone, Massimo Massetti, Iacopo Olivotto, Filippo Crea, Giovanna Liuzzo
The hypertrophic cardiomyopathy phenotype encompasses a heterogeneous spectrum of genetic and acquired diseases characterized by the presence of left ventricular hypertrophy in the absence of abnormal cardiac loading conditions. This "umbrella diagnosis" includes the "classic" hypertrophic cardiomyopathy (HCM), due to sarcomere protein gene mutations, and its phenocopies caused by intra- or extracellular deposits, such as Fabry disease (FD) and cardiac amyloidosis (CA). All these conditions share a wide phenotypic variability which results from the combination of genetic and environmental factors and whose pathogenic mediators are poorly understood so far...
September 2023: Heart Failure Reviews
Marisa Avvedimento, Domenico Angellotti, Federica Ilardi, Attilio Leone, Maria Scalamogna, Domenico Simone Castiello, Rachele Manzo, Andrea Mariani, Maddalena Immobile Molaro, Fiorenzo Simonetti, Carmen Anna Maria Spaccarotella, Raffaele Piccolo, Giovanni Esposito, Anna Franzone
No abstract text is available yet for this article.
July 1, 2023: Heart Failure Reviews
A Pozzi, R Abete, E Tavano, S L Kristensen, F Rea, A Iorio, A Iacovoni, G Corrado, C Wong
The aim of this study was to assess whether angiotensin receptor/neprilysin inhibitor (ARNI) decreases ventricular arrhythmic burden compared to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonist (ACE-I/ARB) treatment in chronic heart failure with reduced ejection fraction (HFrEF) patients. Further, we assessed if ARNI influenced the percentage of biventricular pacing. A systematic review of studies (both RCTs and observational studies) including HFrEF patients and those receiving ARNI after ACE-I/ARB treatment was conducted using Medline and Embase up to February 2023...
June 29, 2023: Heart Failure Reviews
Xiangfeng Guan, Ju Zhang, Guangxin Chen, Guanzhao Zhang, Shuting Chang, Zifan Nie, Wenhao Liu, Tianlong Guo, Yunhe Zhao, Bo Li
Mineralocorticoid receptor antagonists (MRAs) are a cornerstone drug class for heart failure therapy. Several clinical studies have demonstrated its role in heart failure therapy. However, due to the recommendation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors for the treatment of heart failure, there is a lack of sufficient evidence regarding whether MRAs can continue to play a cornerstone role in heart failure treatment. A meta-analysis was performed on subgroups of the DAPA-HF and EMPEROR-Reduced trials...
June 27, 2023: Heart Failure Reviews
Konstantinos Prokopidis, Atiporn Therdyothin, Panagiotis Giannos, Jordi Morwani-Mangnani, Panagiotis Ferentinos, Alexandros Mitropoulos, Masoud Isanejad
Omega-3 fatty acids are potential anti-inflammatory agents that may exert beneficial outcomes in diseases characterised by increased inflammatory profile. The purpose of this study was to comprehensively evaluate the existing research on the effectiveness of n-3 fatty acid supplementation in lowering levels of circulating inflammatory cytokines in patients with heart failure (HF). From the beginning until October 2022, randomised controlled trials (RCTs) were the subject of PubMed, Scopus, Web of Science, and Cochrane Library literature search...
June 20, 2023: Heart Failure Reviews
Jishnu Malgie, Pascal R D Clephas, Hans-Peter Brunner-La Rocca, Rudolf A de Boer, Jasper J Brugts
Multiple landmark trials have helped to advance the treatment of heart failure with reduced ejection fraction (HFrEF) significantly over the past decade. These trials have led to the introduction of four main drug classes into the 2021 ESC guideline, namely angiotensin-receptor neprilysin inhibitors/angiotensin-converting-enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. The life-saving effect of these therapies has been shown to be additive and becomes apparent within weeks, which is why maximally tolerated or target doses of all drug classes should be strived for as quickly as possible...
June 14, 2023: Heart Failure Reviews
Vasileios Anastasiou, Andreas S Papazoglou, Dimitrios V Moysidis, Stylianos Daios, Dimitrios Tsalikakis, George Giannakoulas, Theodoros Karamitsos, Victoria Delgado, Antonios Ziakas, Vasileios Kamperidis
BACKGROUND: Right ventricular (RV) dysfunction is a well-recognized adverse prognostic feature in patients with heart failure (HF). Recently, many single-center studies have demonstrated that RV longitudinal strain assessed using speckle tracking echocardiography might be a powerful prognosticator in HF. OBJECTIVES: To systematically appraise and quantitatively synthesize the evidence of the prognostic value of echocardiographic RV longitudinal strain, across the entire spectrum of left ventricular ejection function (LVEF) in HF...
June 13, 2023: Heart Failure Reviews
Paschalis Karakasis, Konstantinos Pamporis, Panagiotis Stachteas, Dimitrios Patoulias, Konstantinos I Bougioukas, Nikolaos Fragakis
The recently published randomized trials (RCTs) evaluating the effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in heart failure with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) led researchers to perform a plethora of systematic reviews (SRs), often providing contradictory conclusions. This overview of reviews was aimed at summarizing the evidence of these SRs, quantifying the overlap, re-analyzing the evidence in case new studies that were identified, and mapping knowledge gaps...
June 7, 2023: Heart Failure Reviews
Mauro Riccardi, Antonio M Sammartino, Marianna Adamo, Riccardo M Inciardi, Carlo M Lombardi, Nicola R Pugliese, Daniela Tomasoni, Enrico Vizzardi, Marco Metra, Andrew J S Coats, Matteo Pagnesi
Heart failure (HF) with preserved ejection fraction (HFpEF) causes a progressive limitation of functional capacity, poor quality of life (QoL) and increased mortality, yet unlike HF with reduced ejection fraction (HFrEF) there are no effective device-based therapies. Both HFrEF and HFpEF are associated with dysregulations in myocardial cellular calcium homeostasis and modifications in calcium-handling proteins, leading to abnormal myocardial contractility and pathological remodelling. Cardiac contractility modulation (CCM) therapy, based on a pacemaker-like implanted device, applies extracellular electrical stimulation to myocytes during the absolute refractory period of the action potential, which leads to an increase in cytosolic peak calcium concentrations and thereby the force of isometric contraction promoting positive inotropism...
May 18, 2023: Heart Failure Reviews
Parmida Sadat Pezeshki, Seyyed Mojtaba Ghorashi, Golnaz Houshmand, Mojdeh Ganjparvar, Hamidreza Pouraliakbar, Kiara Rezaei-Kalantari, Amir Fazeli, Negar Omidi
Feature-tracking cardiac magnetic resonance (FT-CMR), with the ability to quantify myocardial deformation, has a unique role in the evaluation of subclinical myocardial abnormalities. This review aimed to evaluate the clinical use of cardiac FT-CMR-based myocardial strain in patients with various systemic diseases with cardiac involvement, such as hypertension, diabetes, cancer-therapy-related toxicities, amyloidosis, systemic scleroderma, myopathies, rheumatoid arthritis, thalassemia major, and coronavirus disease 2019 (COVID-19)...
May 16, 2023: Heart Failure Reviews
Jiahua Li, Qi Chen, Rong Zhang, Zhongqiu Liu, Yuanyuan Cheng
Myocardial infarction (MI) is one of the cardiovascular diseases with high morbidity and mortality. MI causes large amounts of apoptotic and necrotic cells that need to be efficiently and instantly engulfed by macrophage to avoid second necrosis. Phagocytic macrophages can dampen or resolve inflammation to protect infarcted heart. Phagocytosis of macrophages is modulated by various factors including proteins, receptors, lncRNA and cytokines. A better understanding of mechanisms in phagocytosis will be beneficial to regulate macrophage phagocytosis capability towards a desired direction in cardioprotection after MI...
May 9, 2023: Heart Failure Reviews
Ali Naveed, Bazigh Naveed, Muhammad Atif Khan, Talal Asif
The twenty-first century has revolutionized the management of congestive heart failure with the widespread use of left ventricular assist devices and other treatment modalities that improve morbidity and mortality after the failure of medical management. These novel devices come with significant side effects. One of the most common side effects of left ventricular assist devices is the increased frequency of lower gastrointestinal bleeding compared to heart failure patients without left ventricular assist devices...
May 5, 2023: Heart Failure Reviews
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.